Rani Therapeutics Holdings

Rani Therapeutics Holdings, Inc. operates as a clinical stage bio-therapeutics company providing technologies to enable the development of orally administered biologics. It offers RaniPill capsule, an orally ingestible pill for the administration of a broad range of biologics. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Rani Therapeutics excels in 2022 with breakthrough drug delivery innovations

Rani Therapeutics made significant strides in 2022 with advancements in their RaniPill platform and promising Phase 1 results for RT-102, positioning the company for future growth.
Despite financial strength and successful partnerships, Rani faces challenges in maintaining clinical success rates, managing expenses, and navigating regulatory requirements.
Opportunities lie in expanding clinical trials, forging new partnerships, and innovating in drug delivery technologies to drive future growth and market expansion for Rani.

Rani Therapeutics excels in drug delivery innovation and clinical progress

Rani Therapeutics demonstrated strong performance in 2023 with positive Phase I results and successful oral delivery achievements, showcasing its innovative capabilities.
While facing challenges in negotiations and pipeline development, Rani has strengths in transformative technology and clinical expertise to navigate the competitive landscape.
With opportunities to expand drug delivery capabilities and strategic collaborations, Rani Therapeutics is poised for growth and advancement in the pharmaceutical sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.

This is the second deal announced between Rani and Celltrion, building upon a previously announced partnership for ustekinumab biosimilar for RT-111 This is the second deal announced between Rani and Celltrion, building upon a previously announced partnership for ustekinumab biosimilar for RT-111

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

SAN JOSE, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company's Chief Executive Officer, Talat Imran, and Chief Financial Officer, Svai Sanford, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023 from 4:00-4:25 pm E.T. in Track 3.

Rani Therapeutics to Present at the Jefferies Healthcare Conference

SAN JOSE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that three submitted abstracts were accepted for poster presentations at the 105th annual meeting of The Endocrine Society (ENDO 2023) taking place June 15-18, 2023, in Chicago, Illinois.

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

SAN JOSE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has appointed Kate McKinley as its Chief Business Officer.

Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

- Announced partnership with Celltrion on development of RT-111, a RaniPill GO capsule containing a biosimilar for the monoclonal antibody ustekinumab -

Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update

Rani Therapeutics Holdings, Inc. has an exciting oral drug delivery system for biologics. It has shown excellent early data in trials.

Rani Therapeutics: Novel Drug Delivery System, Under-Covered And Early Stage

SAN JOSE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company's Chief Executive Officer, Talat Imran, will present at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023 at 12:45 p.m. PT / 3:45 p.m. ET.

Rani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI ) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET Company Participants Laurence Watts - Managing Director, Gilmartin Group LLC Talat Imran - CEO Svai Sanford - CFO Mir Hashim - Chief Scientific Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Hao Shen - Bank of America Andreas Argyrides - Wedbush Annabel Samimy - Stifel Ashwani Verma - UBS Bert Hazlett - BTIG Mitchell Kapoor - H. C. Wainwright Operator Hello, and welcome to Rani Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call.

Rani Therapeutics Holdings, Inc. (RANI) Q4 2022 Earnings Call Transcript

- Anticipates initiating first Phase 2 clinical study in RT-102 in 2H of 2023 -

Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update

Management to host conference call on Wednesday, March 22 at 4:30 p.m. ET Management to host conference call on Wednesday, March 22 at 4:30 p.m. ET

Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Celltrion will be Rani's exclusive supplier of ustekinumab biosimilar, CT-P43, for oral RT-111 RaniPill™ program Celltrion will be Rani's exclusive supplier of ustekinumab biosimilar, CT-P43, for oral RT-111 RaniPill™ program

Celltrion and Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment

- Preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway for RT-102 could be suitable -

Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update

- RT-102 achieved all of its endpoints in the repeat-dose Part 2 of the Phase 1 Study -

Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study

Rani Therapeutics Holdings, Inc. (RANI) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Rani Therapeutics Holdings, Inc. (RANI) Reports Q3 Loss, Lags Revenue Estimates

SAN JOSE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company will present at the Stifel Healthcare Conference taking place on November 15 - 16, 2022.

Rani Therapeutics to Present at the Stifel Healthcare Conference

Rani Therapeutics Holdings, Inc. (RANI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here's Why Rani Therapeutics Holdings, Inc. (RANI) Is a Great 'Buy the Bottom' Stock Now

- Rani announces preclinical development of RT-111, a RaniPill GO capsule containing ustekinumab biosimilar for the potential treatment of psoriatic arthritis, ulcerative colitis, Crohn's disease and psoriasis -

Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update

SAN JOSE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company will present at the H.C. Wainwright Global Investment Conference, taking place September 12 - 14, 2022 virtually and in-person.

Rani Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SAN JOSE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has terminated the underwritten public offering of its Class A common stock previously announced on August 10, 2022. The termination results from an assessment by the Company's management that current market conditions are not conducive for an offering on terms that would be in the best interests of the Company's stockholders. As a result of such termination, no shares of Class A common stock will be sold pursuant to the offering. The Company believes it has sufficient capital and financial flexibility to continue to fund its ongoing operations into mid-2024.

Rani Therapeutics Announces Termination of Public Offering of Class A Common Stock

Rani Therapeutics Holdings, Inc. (RANI) delivered earnings and revenue surprises of -10.71% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Rani Therapeutics Holdings, Inc. (RANI) Reports Q2 Loss, Misses Revenue Estimates

SAN JOSE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics, today announced that it intends to offer and sell shares of its Class A common stock in an underwritten public offering (the “Offering”). Rani Therapeutics expects to grant the underwriters a 30-day option to purchase additional shares up to 15% of the aggregate number of shares offered in the Offering.   The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or the actual size or terms of the Offering.

Rani Therapeutics Announces Proposed Public Offering of Class A Common Stock

- Announced positive topline Phase 1 results of RT-102 for the treatment of osteoporosis -

Rani Therapeutics Reports Second Quarter 2022 Financial Results; Provides Corporate Update

- RT-102 was generally well-tolerated, with no RaniPill™-related adverse events -

Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of RT-102 in Osteoporosis

Extends Rani's projected cash runway into mid-2024 Extends Rani's projected cash runway into mid-2024

Rani Therapeutics Enters into $45 Million Loan Agreement to Support Ongoing RaniPill® Platform Advancement and Clinical Pipeline Development

- Initiated a Phase 1 clinical trial of RT-102 for the treatment of osteoporosis –

News for Rani Therapeutics Holdings Stock (RANI)